Mylan has entered into a sub-licensing agreement with the Medicines Patent Pool (MPP), a UN-backed public health organisation, to expand access to chronic hepatitis C medicines in developing countries.
Under the agreement, announced yesterday, November 28, Mylan will produce and market a generic version of Bristol-Myers Squibb’s Daklinza (daclatasvir).
The generic drug will be distributed in 112 low and middle income countries.
Rajiv Malik, president of Mylan, said: “We’re committed at Mylan to reducing the burden of hepatitis C on communities around the world by providing access to high quality medicines that treat the disease.
He added: “We are pleased to work together with the MPP and Bristol-Myers Squibb to help make daclatasvir available to low and middle income countries at affordable prices.”
According to the statement, 130 to 150 million people have chronic hepatitis C infection and the majority live in low and middle income countries.